Buspirone controlled release - Biovail

Drug Profile

Buspirone controlled release - Biovail

Latest Information Update: 20 Mar 2003

Price : $50

At a glance

  • Originator Biovail Corporation
  • Class Antidepressants; Anxiolytics; Pyrimidines; Small molecules; Spiro compounds
  • Mechanism of Action Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Generalised anxiety disorder

Most Recent Events

  • 20 Mar 2003 Discontinued - Phase-III for Generalised anxiety disorder in Canada (PO)
  • 29 Jun 2000 Phase-III clinical trials for Anxiety disorders in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top